MAX-40279-01 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, non-randomized, open-label, single-arm, dose-escalation Phase I study
to evaluate the safety and tolerability of MAX-40279-01 in patients with advanced solid
tumor.